PHA Pharmagest Interactive SA

EQUASENS: H2 2022 HALF-YEAR REPORT ON THE LIQUIDITY AGREEMENT WITH GILBERT DUPONT

EQUASENS: H2 2022 HALF-YEAR REPORT ON THE LIQUIDITY AGREEMENT WITH GILBERT DUPONT

Villers-lès-Nancy, 20 January 2023 – 6:00 p.m. (CET)

PRESS RELEASE

H2 2022 HALF-YEAR REPORT ON THE LIQUIDITY AGREEMENT

WITH THE BROKERAGE FIRM GILBERT DUPONT

Under the liquidity agreement administered by the brokerage firm, Gilbert Dupont, on behalf of , liquidity account holdings at 30 December 2022 were as follows:

- Number of shares: 3,006

- Cash balance: €122,399.02

For the 2022 second half, a summary of total transactions is provided below:

PURCHASES29,847 shares€2,235,495.18756 transactions
SALES29,620 shares€2,208,567.87827 transactions

For information, liquidity account holdings were reported as follows:

in the half-year report of 30 June 2022:

- Number of shares: 2,676

- Cash balance: €157,148.62

when the liquidity agreement was first implemented:

- Number of shares: 2,219

- Cash balance: €50,000.00

This liquidity agreement is executed in accordance with Decision No. 2021-01 of 22 June 2021 of the Autorité des Marchés Financiers (“AMF”) establishing accepted market practices in relation to the renewal of liquidity agreements for shares, which provisions replace the previous Decision No. 2018-01.

About

With more than 1,200 employees fulfilling a vital role as “Citizens in the Service of Health and Well-Being”, Equasens Group is today a key player in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centres) in both primary and secondary care sectors.

With operations in in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group is currently developing the leading healthcare platform and a unique ecosystem in France and Europe benefiting people by making available the very best of technology.

Listed on Euronext Paris™ - Compartment A

Included in the Euronext Tech Leaders segment and the European Rising Tech label

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable by inclusion

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).

ISIN: FR0012882389 - Ticker Code: EQS

For all the latest news on Equasens Group go to

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique SCHMIDT

Tel. +33 (0)3 83 15 90 67 –

Media Relations:

FIN’EXTENSO - Isabelle APRILE

+33 (0)1 39 97 61 22 -   

APPENDIX

 PurchasesSales
 Number of transactionsNumber of sharesNumber of transactionsNumber of sharesNumber of transactionsNumber of shares
TOTAL75629 8472 235 495,1882729 6202 208 567,87
01/07/20228190145001937929232,8
04/07/20222038529712,99819114870,21
05/07/2022029822809,19013410416,2
06/07/2022021416301,41030423415,11
07/07/20220251937,5031624759,01
08/07/202251108684,011729723621,6
11/07/2022414111239,51116713395,3
12/07/20221036529332,21137930644,08
13/07/20221846637308,61721517069,3
14/07/2022021717142,3901007950
15/07/2022013610724,29015812447,3
18/07/2022020016012,4040532405,91
19/07/2022039831387,71036828987,8
20/07/2022025820612,6037629847,9
21/07/20220887216028723204,61
22/07/2022025921305,81014011554,4
25/07/2022017214172,09021517860,01
26/07/2022030825758,59027122704
27/07/2022039232737,290857123
28/07/2022519215990,61222218628,8
29/07/20221218815866,091628924517,89
01/08/20222241434873,7423520351
02/08/2022040733506,40473924,5
03/08/2022026221495,11051943186,92
04/08/2022016013482,8018215415
05/08/2022050041699,9013011042,01
08/08/2022015012174019616030,6
09/08/2022029323984,39021417728,4
10/08/2022021117173,8027122267,5
11/08/2022021217520,1015813124,7
12/08/2022024019702,61013711285,8
15/08/2022018415265,01046439191,99
16/08/2022018715552027723183,4
17/08/2022022618784,19026722291,59
18/08/2022032626970,11015012552
19/08/2022019015620,3023019008,01
22/08/2022026821750,8000
23/08/2022019915885,79014811863,61
24/08/202201088615,6035528709,6
25/08/20220685564,5019916422,69
26/08/2022030424780,99000
29/08/2022024019148,69000
30/08/2022019615334,101068359,2
31/08/2022024619143,4018314289,3
01/09/2022013810561,60175,8
02/09/20220161209,6036628427
05/09/2022021616701,1000
06/09/2022019515080,7025019383,7
07/09/202201098411,6024018680,21
08/09/2022000036829109,5
09/09/202201239801,4017013625,01
12/09/2022018514737,51024519643,51
13/09/2022041732995,7901219691,89
14/09/2022028421898,5901078305,7
15/09/2022019714893,1000
16/09/2022036226569,79037327493,38
19/09/2022015311022016912198,79
20/09/2022022015831,901158273,5
21/09/20220614342,7035125292,71
22/09/2022032223037,720251802,5
23/09/2022029820766,49024617609,69
26/09/2022029920359,9901389521,7
27/09/2022022314728,1901419390,9
28/09/2022019812535,50503117,5
29/09/202201579516,1901519152,09
30/09/202201317804,8043426316,41
03/10/2022026315662,81028917325,41
04/10/202201006040041425705,59
05/10/20222437023418,4881529801,7
06/10/2022817811140,0181438991,2
07/10/2022029418332,61016810598,1
10/10/20222638323460,592804944
11/10/2022021112431,8019011265,1
12/10/20221621612642,22224114144,8
13/10/2022711064702336821942,11
14/10/20222321962,91628117406,91
17/10/20224976035,41725015784,6
18/10/20220001930919993,81
19/10/2022028618456,3019212442
20/10/20228785021,6919612717,4
21/10/20220372393,9026817573,7
24/10/20221927918274,811833021722,61
25/10/20221524116185,11837525017,79
26/10/20221322615349,312348232948,89
27/10/20221929420310,112941528729,41
28/10/20222543730203,521233523156,1
31/10/20221238727414,312242029529,32
01/11/20221122616354,63041229764,98
02/11/20222944332223,912534525197,7
03/11/2022046833843,28035025315,19
04/11/20222862044549,293550235806,41
07/11/2022017212147,4026418776,21
08/11/2022034224217,19040829097,58
09/11/20221533023378,09101067569,4
10/11/20221737225957,92156039946,98
11/11/20227705270,32635126630,69
14/11/20221033525897,912539430663,8
15/11/202223400308753282170
16/11/20222336727798,712221694
17/11/20221123117090,1121259294,2
18/11/202261007383,52731623684,48
21/11/2022023017258,6023317558,6
22/11/20221221665,41722817492,3
23/11/20221832024550,91816512696,5
24/11/20221736928185,511020815972,4
25/11/20225886705,61928121798,21
28/11/2022028822039,80171303,9
29/11/2022019514862027420975,3
30/11/20220806122,5037829351,21
01/12/20222534926908,811113810693,61
02/12/2022026420137,2101088277,9
05/12/2022818013725,22031323934,52
06/12/2022041931497,190211543,5
07/12/20221219714356,21227219869,3
08/12/20221416011679,51613710054,5
09/12/20223755487,52226919881,2
12/12/2022019014046,21031723560,3
13/12/20221122116455,591628521401,59
14/12/20221514911129,5916512385
15/12/20221419714699,1414010443,01
16/12/20222033524648,34805932
19/12/20222131622762,817805819,6
20/12/2022015010733,401339537,7
21/12/202215035802831022517,69
22/12/202291329720,11419714609,5
23/12/20221916311976,710705152,7
26/12/2022000000
27/12/20220997360,1028821411,01
28/12/20221725919198,895614483,5
29/12/202296547752140830327,21
30/12/20223539329448,79713610237,4

Attachment



EN
20/01/2023

Underlying

PHAPharmagest Interactive SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

Arnaud Riverain
  • Arnaud Riverain
PHA Pharmagest Inte...

EQUASENS (EQS) - CA S1 : Retour de la dynamique confirmé / Achat - Obj...

CA S1 +7,4% à 116 M€ en ligne (115,4 M€ attendus) T1 : 57 M€, +6,9% (+5,9% pc) T2 : 58,9 M€, +7,8% (+6,9% pc) Apport de Calimed 1,1 M€ Intégration ResUrgenves & DIS à compter du 1er juillet.

PHA PHARMAGEST INTERACTIVE SA
08/01/25 August 1, 2025 EN
 PRESS RELEASE
Free
PHA Pharmagest Inte...

Equasens: H1 revenue at 30 June 2025: €116.0m

Equasens: H1 revenue at 30 June 2025: €116.0m Villers-lès-Nancy (France), 31 July 2025 - 6:00 PM (CET) PRESS RELEASE H1 revenue at 30 June 2025: €116.0m+7.4% on a reported basis and +6.4% like-for-like H1 2025 Group revenue (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Q153.357.03.76.9%0.53.25.9%Q254.758.94.37.8%0.53.86.9%Total108.0116.08.07.4%1.16.96.4%H1 2025 revenue / Division (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growthPharmagest82,1...

July 31, 2025 1 EN
 PRESS RELEASE
Free
PHA Pharmagest Inte...

EQUASENS : Chiffre d’affaires au 30 juin 2025 à 116,0 M€

EQUASENS : Chiffre d’affaires au 30 juin 2025 à 116,0 M€ Villers-lès-Nancy, le 31 juillet 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Chiffre d’affaires au 30 juin 2025 à 116,0 M€+7,4% en croissance publiée et + 6,4% en croissance organique CA S1 2025 Groupe (M€)Publié 2024Publié 2025Variation /publiéDont Croissances externesVariation /périmètre comparable (croissance organique)T153,357,03,76,9%0,53,25,9%T254,758,94,37,8%0,53,86,9%Total108,0116,08,07,4%1,16,96,4%CA S1 2025 / Division (M€)Publié 2024Publié 2025Variation /publiéDont Croissances externesVariation /périmètre comparable (croissan...

July 31, 2025 1 EN
 PRESS RELEASE
Free
PHA Pharmagest Inte...

Equasens: Appointment at the head of the Pharmagest Division

Equasens: Appointment at the head of the Pharmagest Division Villers-lès-Nancy (France), July 03, 2025 – 06 :00pm (CET) Press Release Equasens announces the departure of Damien VALICON, as Deputy Chief Executive Officer and Director of the Pharmagest Division He will be replaced by François-Pierre MARQUIER as Director of the Pharmagest Division. *** (Euronext Paris™ - Compartment B - FR 0012882389 –$EQS), announces the departure of Damien VALICON, who held the position of Deputy Chief Executive Officer and Director of the Pharmagest Division for 18 months, and the appointment of Fran...

July 3, 2025 1 EN
 PRESS RELEASE
Free
PHA Pharmagest Inte...

EQUASENS : Nomination à la direction de la Division Pharmagest

EQUASENS : Nomination à la direction de la Division Pharmagest Villers-lès-Nancy, le 03 juillet 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Equasens annonce le départ de Damien VALICON, Directeur Général Délégué et Directeur de la Division PHARMAGEST Il sera remplacé par François-Pierre MARQUIER en tant que Directeur de la Division Pharmagest *** (Euronext Paris™ - Compartiment B - FR 0012882389 –$EQS), annonce le départ de Damien VALICON, qui occupait depuis 18 mois les fonctions de Directeur Général Délégué du Groupe et de Directeur de la Division PHARMAGEST, ainsi que la nomination de...

July 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch